Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment

Autor: Erik Thunnissen, Jamie J. Beagan, Sander Bach, D. Michiel Pegtel, Bauke Ylstra, Daniëlle A.M. Heideman, Janneke Weiss, Geert Kazemier, Daan van den Broek, Robert A. A. van Boerdonk, Erik van Dijk, Idris Bahce

Publikováno v: Beagan, J J, Bach, S, van Boerdonk, R A, van Dijk, E, Thunnissen, E, van den Broek, D, Weiss, J, Kazemier, G, Pegtel, D M, Bahce, I, Ylstra, B & Heideman, D A M 2020, ' Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment ', Lung Cancer, vol. 145, pp. 173-180 . https://doi.org/10.1016/j.lungcan.2020.04.039, https://doi.org/10.1016/j.lungcan.2020.04.039
Lung Cancer, 145, pp. 173-180
Lung Cancer, 145, 173-180. Elsevier Ireland Ltd
Beagan, J, Bach, S, van Boerdonk, R A A, van Dijk, E, Thunnissen, E, van den Broek, D, Weiss, J, Kazemier, G, Pegtel, D M, Bahce, I, Ylstra, B & Heideman, D A M 2020, ' Circulating Tumour DNA Analysis of EGFR-Mutant Non-Small Cell Lung Cancer Patients Receiving Osimertinib Following Previous Tyrosine Kinase Inhibitor Treatment ', Journal of Molecular Diagnostics, vol. 22, no. 5, pp. S56-S56 .
Journal of Molecular Diagnostics, 22(5), S56-S56. Association of Molecular Pathology
Lung Cancer, 145, 173-180

Objectives: Circulating tumor (ct)DNA analysis is rapidly gaining acceptance as a diagnostic tool to guide clinical management of advanced non-small cell lung cancer (NSCLC). Clinically-actionable EGFR mutations can be detected in ctDNA before or aft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51cc481059e261999370f611edb94ac3
https://hdl.handle.net/2066/220047

Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors

Autor: Jan P. A. Baak, Gerrit A. Meijer, Jan W. W. Walboomers, Paul J. van Diest, Peter J.F. Snijders, Mario A. J. A. Hermsen, Janneke Weiss

Publikováno v: The Journal of Pathology. 186:356-362

Within the subgroup of lymph node-negative breast cancers, there is a need for accurate prognostic indicators to select high-risk patients. Comparative genomic hybridization (CGH) provides an opportunity to screen the whole genome for chromosomal abe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8a02e2952e52fde33de49aee1e74e9f
https://doi.org/10.1002/(sici)1096-9896(199812)186:4<356::aid-path196>3.0.co